Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

BACKGROUND: The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options for patients with locally advanced or metastatic urothelial carcinoma. Avelumab, a human monoclonal anti-PD-L1 antibody, has shown promising antitumour activity and sa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Patel, Manish R, Ellerton, John, Infante, Jeffrey R, Agrawal, Manish, Gordon, Michael, Aljumaily, Raid, Britten, Carolyn D, Dirix, Luc, Lee, Keun-Wook, Taylor, Mathew, Schöffski, Patrick, Wang, Ding, Ravaud, Alain, Gelb, Arnold B, Xiong, Junyuan, Rosen, Galit, Gulley, James L, Apolo, Andrea B
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7984727/
https://ncbi.nlm.nih.gov/pubmed/29217288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30900-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados